GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Incannex Healthcare Ltd (STU:IQI) » Definitions » Gross Margin %

Incannex Healthcare (STU:IQI) Gross Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Incannex Healthcare Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Incannex Healthcare's Gross Profit for the three months ended in Mar. 2024 was €0.00 Mil. Incannex Healthcare's Revenue for the three months ended in Mar. 2024 was €0.00 Mil. Therefore, Incannex Healthcare's Gross Margin % for the quarter that ended in Mar. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Incannex Healthcare's Gross Margin % or its related term are showing as below:


During the past 13 years, the highest Gross Margin % of Incannex Healthcare was 51.96%. The lowest was -82.95%. And the median was 48.25%.

STU:IQI's Gross Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 46.405
* Ranked among companies with meaningful Gross Margin % only.

Incannex Healthcare had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Incannex Healthcare was 0.00% per year.


Incannex Healthcare Gross Margin % Historical Data

The historical data trend for Incannex Healthcare's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incannex Healthcare Gross Margin % Chart

Incannex Healthcare Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.19 50.68 25.47 51.94 -

Incannex Healthcare Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Incannex Healthcare's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Incannex Healthcare's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incannex Healthcare's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Incannex Healthcare's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Incannex Healthcare's Gross Margin % falls into.



Incannex Healthcare Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Incannex Healthcare's Gross Margin for the fiscal year that ended in Jun. 2022 is calculated as

Gross Margin % (A: Jun. 2022 )=Gross Profit (A: Jun. 2022 ) / Revenue (A: Jun. 2022 )
=-0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0.004) / 0
= %

Incannex Healthcare's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Incannex Healthcare  (STU:IQI) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Incannex Healthcare had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Incannex Healthcare Gross Margin % Related Terms

Thank you for viewing the detailed overview of Incannex Healthcare's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Incannex Healthcare (STU:IQI) Business Description

Traded in Other Exchanges
Address
8 Century Circuit Norwest, Suite 105, Sydney, NSW, AUS, 3000
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products.